European equities traded in the US as American depositary receipts were moving higher late Thursday morning, rising 0.57% to 1,294.83 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by telecommunications company VEON (VEON) and biotech firm Evaxion Biotech (EVAX), which climbed 7.3% and 6.3% respectively. They were followed by petroleum refiner Equinor (EQNR) and biopharmaceutical company Genfit (GNFT), which rose 3.7% and 2.9% respectively.
The decliners from continental Europe were led by financial services companies Banco Bilbao Vizcaya Argentaria (BBVA) and Banco Santander (SAN), which fell 2.2% and 1.8% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and software firm SAP (SAP), which dropped 1.7% and 0.6% respectively.
From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN), which advanced 15%, followed by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which rose 13% each. They were followed by biopharmaceutical company Amarin (AMRN), which increased 9.3%.
The decliners from the UK and Ireland were led software firm by Endava (DAVA) and financial services company HSBC (HSBC), which lost 1.3% and 1% respectively. They were followed by alcoholic beverages company Diageo (DEO) and biopharmaceutical company TC Biopharm (TCBP), which were off 0.8% and 0.5% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。